ICS在新冠治疗中的作用 吸入性糖皮质激素组患者临床恢复时间显著短于常规治疗组 ICS与新冠常用药物的相互作用 专家点评:参考文献: [1] 中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版) [2] 北京协和医院.北京协和医院新型冠状病毒感染基层诊疗方案建议及适宜技术(第一版[2023.1.3]) [3] Klimek L, Buhl R, Deitmer T, et al. Recommendations for use of topical inhalant budesonide in COVID-19 : A Position Paper of the German Society for Applied Allergology (AeDA) and the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO). HNO. 2021 Aug;69(Suppl 2):35-38. [4] Li X, Ma X. Acute respiratory failure in COVID-19: is it 'typical' ARDS? Crit Care. 2020 May 6;24(1):198. [5] Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Jul;9(7):763-772. [6] Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Aug 10:S0140-6736(21)01744-X. [7] Matsuyama S, Kawase M, Nao N, et al. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. J Virol. 2020 Dec 9;95(1):e01648-20. [8] GINA UPDATED 2020. appendix P35 [9] Tamm M, Richards DH, Beghé B, et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012 Dec;106 Suppl 1:S9-19. [10] 奈玛特韦/利托那韦说明书 [11] 申昆玲,邓力,李云珠,等. 糖皮质激素雾化吸入疗法在儿科应用的专家共识(2018年修订版)[J]. 临床儿科杂志,2018,36(2):95-107. [12]https:///checker [13] Ong CK, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007 Mar;5(1):19-34. [14] 对乙酰氨基酚说明书 |
|